Early Results from the Phase II C10403 Trial of Combination Chemotherapy for Older Adolescents and Young Adults with Newly Diagnosed ALL
CME INFORMATION

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

Although original data are consistently being presented and published, the flood of information unveiled during a major academic conference is unprecedented and leaves in its wake an enormous volume of new knowledge that practicing oncologists must try to sift through, evaluate and consider applying. Unfortunately and quite commonly, time constraints and an inability to access these data sets leave many oncologists struggling to ensure that they’re aware of crucial practice-altering findings. This creates an almost insurmountable obstacle for clinicians in community practice because they are not only confronted almost overnight with thousands of new presentations and data sets to consider but they are also severely restricted in their ability to review and interrogate the raw findings.

To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets on up-front and salvage therapeutic options and modalities for the evaluation of treatment response in newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL) and myelodysplastic syndromes (MDS) from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts may be applied to routine clinical care. This activity will assist medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES

- Evaluate the results of the confirmatory Phase II BLAST study of blinatumomab in patients with relapsed/refractory ALL, and consider this information when developing treatment plans for these patients.
- Analyze the efficacy of a more intensive pediatric chemotherapy regimen for older adolescents and young adults with newly diagnosed B- or T-precursor ALL, and determine the feasibility of this approach for patients with ALL in this age group.
- Compare and contrast the benefits and risks reported in the Phase III APL0406 trial of all-trans retinoic acid (ATRA) with arsenic trioxide versus ATRA with chemotherapy, and consider the potential therapeutic benefit of a chemotherapy-free regimen for patients with newly diagnosed nonhigh-risk APL.
- Determine the clinical benefit seen with the addition of the multikinase inhibitor sorafenib to standard primary induction and consolidation therapy for younger patients with newly diagnosed AML.
- Assess the efficacy and tolerability profile of the novel agent vosaroxin combined with cytarabine from the Phase III VALOR trial in patients with relapsed or refractory AML.
- Examine the impact of lenalidomide therapy on the achievement of transfusion independence in red blood cell transfusion-dependent patients with lower-risk MDS without del(5q).

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJCASH2015/5/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Mikkael A Sekeres, MD, MS
Professor of Medicine
Director, Leukemia Program
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Advisory Committee: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim...

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Seattle Genetics and Takeda Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: May 2015
Expiration date: May 2016
Not long after this year’s American Society of Hematology (ASH) meeting, we gathered 6 clinical investigators for our first ever think tank focused exclusively on leukemias and myelodysplastic syndromes (MDS). Although a lot of the excitement during this closed recording session centered on new agents and therapies — particularly the explosion of encouraging clinical research in acute lymphoblastic leukemia (ALL) with both CAR T-cell immunotherapy and the bispecific T-cell engager antibody blinatumomab (see below) — it was also fascinating to hear that an older drug that has sometimes gotten a bad rap — sorafenib (sor) — may have a new role as part of up-front treatment for acute myeloid leukemia (AML).

ALL is an uncommon disease that many oncologists appropriately triage to tertiary centers, but AML — particularly in elderly patients — is an important part of general oncology practice. As such, even though the randomized, Phase II trial of sor presented at ASH as a plenary was not the “home run” that we are beginning to see more frequently with immunotherapy in many diseases, from a practical clinical perspective the study findings may be among the most important in any cancer this year.

For that reason, we lead off this year’s acute leukemia/MDS ASH summary by focusing on that work. But as always, we also created teaching slide sets and obtained perspectives from a noted clinical investigator — in this case Mikkael Sekeres — for a number of the most important presentations, which are outlined below:

**AML**

**Sor up front in AML**

About 20% of patients with AML have activating mutations in the FMS-like tyrosine kinase 3 (FLT3), and a number of FLT3 inhibitors are in various states of development. Sor targets this kinase, among others, and for that reason this [Phase II placebo-controlled German trial](#) evaluated the addition of sor to standard induction and consolidation treatment (followed by maintenance with sor) in 267 adult patients with...
newly diagnosed AML age 60 years and younger. Importantly, individuals both with and without FLT3-internal tandem duplication (ITD) mutations were eligible for and enrolled in the study. With a median follow-up of 3 years, the trial met its primary endpoint of event-free survival (EFS), demonstrating a significant improvement in favor of sor (median EFS 20.5 months versus 9.2 months, \( p = 0.013 \)). Interestingly and quite unexpectedly, there was a suggestion that the benefit was, if anything, more impressive in patients without FLT3-ITD mutations. The one sticking point is, to date there is no overall survival (OS) advantage, which is concerning to Dr Sekeres and has informed his current decision not to use up-front sor outside of a clinical trial.

However, at the think tank the reaction to these data was quite different, as Dr Hagop Kantarjian noted that since 2005, he and his MD Anderson colleagues have been routinely using FLT3 inhibitors in patients with FLT3-ITD mutations and that the outcomes appear indirectly to be improved compared to earlier series. The think tank faculty speculated on possible biologic explanations for these compelling findings, including the presence of other kinase targets or inhibition of wild-type FLT3 kinase activation, but most seemed to agree that these new data at the very least deserve careful consideration in patients with and without these abnormalities. To further drive home this point, Dr Kantarjian made an impassioned plea for “leukemia doctors to act more like those focused on solid tumors” and seek small research advances that, when coupled together, create a major positive effect for patients, as seen, for example, in renal cell carcinoma.

**VALOR trial of vosaroxin**

VALOR is a large, international Phase III study evaluating cytarabine with or without vosaroxin, a first-in-class anticancer quinolone derivative, in patients with relapsed/refractory AML. On the surface things look straightforward, as the trial did not reach its primary endpoint of improved OS. However, the data also demonstrated that complete remission rates were improved with vosaroxin/cytarabine, and a preplanned survival subgroup analysis censoring patients at allogeneic transplant showed a statistically significant 1.4-month advantage (hazard ratio 0.83, \( p = 0.02 \)). Dr Sekeres is not convinced these improvements are clinically meaningful, but Dr Kantarjian — whose group has done a lot of this research — believes vosaroxin has important value and should be made available to clinicians.

**MDS**

**Lenalidomide (len) in non-del(5q) disease**

While the role of this immunomodulatory agent is well established and approved in patients with del(5q), mainly for management of anemia, a prior Phase II trial
suggested clear-cut benefit in non-del(5q) disease. **This Italian Phase III study** almost duplicated the results seen in the Phase II effort and demonstrated a ≥56-day transfusion independence rate of 27% with len compared to a 2.5% rate with placebo. These findings will undoubtedly lead clinicians to want to use this drug in this situation, and think tank participant Dr David Steensma endorses this approach. However, he cautions that “platelets need to be at a reasonable level” to use len.

**Azacitidine (aza) alone or with len or vorinostat (vor) in higher-risk MDS and chronic myelomonocytic leukemia**

At ASH Dr Sekeres presented the first results from the largest prospective study in higher-risk MDS ever conducted in North America — **SWOG-S1117** — which demonstrated a modest signal for improvement in disease-related outcomes with the 2 combinations. Unfortunately, a greater likelihood to discontinue treatment due to toxicity was also seen (9% aza, 23% aza/len, 24% aza/vor). In discussing this work, Dr Sekeres pointed out that these data will continue to mature, and he believes it is possible that with better management of side effects, these and other combinations may be successfully incorporated into treatment.

**ATRA/arsenic trioxide (AAT) in acute promyelocytic leukemia (APL)**

At the 2012 ASH meeting, the initial findings from the landmark Phase III Italian-German APL0406 trial in low/intermediate-risk APL comparing AAT as induction and consolidation to ATRA/idarubicin as induction, consolidation and maintenance therapy grabbed headlines and led many oncologists to change their practices. Dr Sekeres and his Cleveland Clinic group, however, wanted to see more follow-up before following suit. That information came **at this year’s meeting** as excellent outcomes (now with 254 patients evaluable for response at 3 years) were observed with both therapies, but there appeared to be a suggestion of greater benefit with AAT (complete response [CR] 100% versus 97%; 2-year EFS rate 98% versus 84.9%, \( p = 0.0002 \); 2-year OS rate 99.1% versus 94.4%, \( p = 0.01 \)). This has now given Dr Sekeres and his group enough supporting evidence to offer the chemotherapy-free AAT combination as standard induction and postremission therapy to patients with low/intermediate-risk APL.

**ALL**

**Treatment for older adolescents and young adults (AYAs)**

For years, a fundamental issue in this disease has been whether more intensive pediatric regimens should be used in AYAs. At ASH we saw relevant findings from the single-arm **US Intergroup trial C10403** of 296 patients age 16 to 39 who received a pediatric regimen administered by adult hematologist-oncologists. The 2-year EFS of 66% seen in this study represents a significant improvement compared to 34% EFS observed in historical controls, and globally the outcomes, including toxicities, were similar to what has been documented in other prospective international studies of pediatric regimens in AYAs.
As a result of these important findings, Dr Sekeres and the think tank faculty, including Dr Wendy Stock, who presented these data at ASH, all support the use of this approach moving forward both in clinical practice and in trials attempting to integrate new agents. It should also be noted that Dr Kantarjian believes that hyper-CVAD is an equivalent alternative.

**CD19-targeted 19-28z CAR-modified autologous T cells in adult patients with relapsed, refractory B-cell ALL**

A number of our CME programs have helped chronicle the amazing story of CAR T-cell therapy, and we would be remiss to not provide an update coming out of the year’s biggest meeting. As previously mentioned, ALL is the locus where this therapy has taken off, and in San Francisco we saw extended follow-up from a Phase I Memorial Sloan Kettering study in this disease. Of the 22 patients evaluable for response, many of whom had heavily pretreated disease, an impressive 91% (20 patients) achieved CR after CAR T-cell infusion, with 90% (18 patients) of those being MRD-negative. Ten of the 13 transplant-eligible patients subsequently went on to successfully receive an allogeneic hematopoietic cell transplant.

In terms of complications, patients with MRD at the time of treatment did not experience cytokine release syndrome (CRS), and for those with morphologic disease at the time of T-cell infusion, a temporal relationship between serum IL-6 levels and CRS suggests that early intervention with IL-6-directed therapy might be effective in ameliorating related neurologic toxicities.

In commenting on this study, Dr Sekeres cautions that currently CAR T-cell therapy requires specialized administration logistics and the capability to manage potentially challenging cytokine-mediated toxicities. He also questions the long-term durability of response and envisions a future for this approach as a bridge to transplant but is uncertain as to whether CAR T-cell therapy will one day have a role as a stand-alone treatment or as part of induction.

**Blinatumomab**

At ASH we saw the presentation of the Phase II BLAST trial of 116 patients who were MRD-positive (≥10^-3) after having received at least 3 prior intensive chemotherapy regimens. The MRD CR after 1 cycle of blinatumomab was 78% and did not differ across multiple patient demographics, including those with higher MRD burden. However, the adverse event (AE) profile (mainly related to cytokine release) is not insignificant. Importantly, in this trial serious AEs occurred in 60% of patients, with 2 fatalities.

In discussing the recent FDA accelerated approval of the drug at the think tank, the faculty noted its impressive effectiveness as a salvage therapy but also related the challenges they have faced in managing toxicities. In this regard, Dr Steensma emphasized the role of corticosteroids in mitigating side effects such as fever and impaired mental function. Not surprisingly, a number of current trials combine...
blinatumomab with chemotherapy in both the salvage and front-line settings, including a Phase III trial in newly diagnosed ALL (NCT02003222).

Be on the lookout for the entire think tank program this summer, but next on this series, we talk about new agents in multiple myeloma, particularly the search for the “rituximab of myeloma” that includes a new wave of monoclonal antibodies such as elotuzumab and daratumumab.

Neil Love, MD
Research To Practice
Miami, Florida
Early Results from the Phase II C10403 Trial of Combination Chemotherapy for Older Adolescents and Young Adults with Newly Diagnosed ALL

Presentation discussed in this issue

Stock W et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): Early results of US Intergroup trial C10403. *Proc ASH* 2014;Abstract 796.

Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Mikkael A Sekeres, MD, MS (1/20/15)

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of US Intergroup Trial C10403

Stock W et al.

*Proc ASH* 2014;Abstract 796.
Background

- ALL is relatively rare among the AYA population of patients but is the most commonly diagnosed form of leukemia in childhood.

- Retrospective analyses have demonstrated significantly improved survival for AYA patients with ALL aged 16-20 years when treated on pediatric versus adult US NCI Cooperative group regimens (Blood 2008;112:1646).

- **Study objective:** To evaluate the feasibility and effectiveness of administering treatment to patients with AYA ALL aged 16-39 years with the standard arm of the successful Children's Oncology Group regimen (COG AALL0232) (Proc ASCO 2011;Abstract 3).

Stock W et al. Proc ASH 2014;Abstract 796.

US Intergroup Phase II C10403
Trial Design (NCT00558519)

<table>
<thead>
<tr>
<th>Eligibility (n = 296)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newly diagnosed B- or T-precursor ALL</td>
</tr>
<tr>
<td>Age 16-39 years</td>
</tr>
<tr>
<td>No Burkitt-type leukemia</td>
</tr>
<tr>
<td>No Ph+ ALL known at diagnosis</td>
</tr>
</tbody>
</table>

4 intensive courses including chemotherapy and radiation therapy:

- Remission induction (I) Tx
- Remission consolidation (C) Tx
- Interim maintenance (IM) Tx
- Delayed intensification (DI) Tx
- Prolonged maintenance (M) Tx

- Patients with M2 marrow response (>5% but <25% lymphoblasts) after remission induction received an extended remission induction course of Tx.

- **Primary endpoints** include event-free survival (EFS), overall survival (OS) and safety.

- Key correlative science studies in a subset of patients included the assessment of minimal residual disease (MRD).

Stock W et al. Proc ASH 2014;Abstract 796.
**US Intergroup Study C10403**

**Chemotherapy Regimen**

<table>
<thead>
<tr>
<th>Column</th>
<th>Treatment 1</th>
<th>Treatment 2</th>
<th>Treatment 3</th>
<th>Treatment 4</th>
<th>Treatment 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>DNR</td>
<td>Cyclo</td>
<td>MTX</td>
<td>DOX</td>
<td>DEX</td>
</tr>
<tr>
<td></td>
<td>VCR</td>
<td>VCR</td>
<td>VCR</td>
<td>Cyclo</td>
<td>VCR</td>
</tr>
<tr>
<td>Pred</td>
<td>Dex</td>
<td>Peg-Asp</td>
<td>Peg-Asp</td>
<td>Dex</td>
<td>6MP</td>
</tr>
<tr>
<td>Peg-Asp</td>
<td>Ara-C</td>
<td>IT-MTX</td>
<td>IT-MTX</td>
<td>Peg-Asp</td>
<td>MTX</td>
</tr>
<tr>
<td>IT-MTX</td>
<td>6MP</td>
<td>IT-MTX</td>
<td></td>
<td>Ara-C</td>
<td>IT-MTX</td>
</tr>
<tr>
<td>IT-AraC</td>
<td></td>
<td></td>
<td></td>
<td>6-TG</td>
<td></td>
</tr>
</tbody>
</table>

*Patients with T-precursor ALL receive prophylactic radiation therapy after DI. Maintenance therapy continues for 2 to 3 years.*

---

**Overall Survival (All Patients)**

![Graph showing overall survival](image)

- **All Patients**
  - N = 296, Events = 71
  - Median OS: Not reached
  - 2 year OS Rate: 79% (95% CI: 74%, 84%)

*With permission from Stock W et al. *Proc ASH* 2014;Abstract 796.*
Event-Free Survival (All Patients)

All Patients
N = 296, Events = 110
Median EFS: 59 months (95% CI: 38, NA)
2 year EFS Rate: 66% (95% CI: 61%, 72%)

With permission from Stock W et al. Proc ASH 2014;Abstract 796.

Event-Free Survival: Subgroup Analysis

By Subtype of ALL

By AYA Age Group

With permission from Stock W et al. Proc ASH 2014;Abstract 796.
Correlation of BCR-ABL1-Like Signature with EFS

- The BCR-ABL1-like signature occurred in 28% of patients and is associated with poor EFS.

With permission from Stock W et al. Proc ASH 2014;Abstract 796.

---

Correlation of MRD After Induction Therapy with Disease-Free Survival (DFS)

- The absence of MRD after induction therapy was associated with excellent DFS.

With permission from Stock W et al. Proc ASH 2014;Abstract 796.
### Univariate Analyses of OS and EFS According to Subgroups

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>OS</th>
<th>EFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>T-cell (vs B-cell)</td>
<td>1.03 (0.60, 1.79)</td>
<td>0.90 (0.57, 1.42)</td>
</tr>
<tr>
<td>Age: 21-29 yo (vs ≤20)</td>
<td>1.63 (0.87, 3.05)</td>
<td>1.63 (0.99, 2.68)</td>
</tr>
<tr>
<td>Age: 30-39 yo (vs ≤20)</td>
<td>1.68 (0.82, 3.45)</td>
<td>1.66 (0.94, 2.94)</td>
</tr>
<tr>
<td>BMI 30-40 (vs &lt;30)</td>
<td>1.77 (1.04, 3.01)</td>
<td>1.16 (0.75, 1.80)</td>
</tr>
<tr>
<td>BMI 40+ (vs &lt;30)</td>
<td>3.81 (1.97, 7.35)</td>
<td>2.13 (1.17, 3.85)</td>
</tr>
<tr>
<td>Obese (BMI &gt;30) (vs not)</td>
<td>2.19 (1.37, 3.49)</td>
<td>1.36 (0.92, 2.00)</td>
</tr>
<tr>
<td>Male (vs female)</td>
<td>0.85 (0.53, 1.36)</td>
<td>0.90 (0.61, 1.21)</td>
</tr>
<tr>
<td>Hispanic (vs non-Hispanic)</td>
<td>1.19 (0.63, 2.22)</td>
<td>1.43 (0.89, 2.31)</td>
</tr>
<tr>
<td>WBC ≥30 (vs &lt;30)</td>
<td>1.57 (0.95, 2.57)</td>
<td>1.76 (1.18, 2.62)</td>
</tr>
<tr>
<td>Ph-like (vs not)</td>
<td>1.34 (0.58, 3.09)</td>
<td>2.12 (1.03, 4.39)</td>
</tr>
<tr>
<td>High CRLF2 (vs not)</td>
<td>2.57 (1.08, 6.16)</td>
<td>3.41 (1.62, 7.18)</td>
</tr>
</tbody>
</table>

Stock W et al. *Proc ASH* 2014;Abstract 796.

### Comparison of Grade 3 to 5 Adverse Events with the COG AALL0232 Study

<table>
<thead>
<tr>
<th>Event</th>
<th>Induction only C10403</th>
<th>AALL0232</th>
<th>All treatments C10403</th>
<th>AALL0232</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperglycemia</td>
<td>29.2%</td>
<td>22.0%</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Abnormal bilirubin</td>
<td>16.4%</td>
<td>6.7%</td>
<td>25.7%</td>
<td>25%</td>
</tr>
<tr>
<td>Abnormal ALT/AST</td>
<td>26.6%</td>
<td>N/A</td>
<td>54.3%</td>
<td>49%</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>3.0%</td>
<td>1.5%</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>1.1%</td>
<td>0.5%</td>
<td>4.2%</td>
<td>3.8%</td>
</tr>
<tr>
<td>CNS hemorrhage</td>
<td>1.0%</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Neuropathy</td>
<td>N/A</td>
<td>N/A</td>
<td>15.7%</td>
<td>11.4%</td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>N/A</td>
<td>N/A</td>
<td>9.6%</td>
<td>19%</td>
</tr>
<tr>
<td>Osteonecrosis</td>
<td>N/A</td>
<td>N/A</td>
<td>2.5%</td>
<td>3.2%</td>
</tr>
</tbody>
</table>

- Overall, treatment-related mortality in the C10403 study was 3%

Stock W et al. *Proc ASH* 2014;Abstract 796.
Author Conclusions

- The pediatric ALL regimen administered by adult patient hematologists/oncologists was validated in this large North American Intergroup trial.
- The study showed significant improvements in survival outcomes in comparison to a 34% EFS for historical controls in CALGB trials (Blood 2008;112:1646).
  - 2-year EFS rate: 66%
  - 2-year OS rate: 79%
- A median EFS of 59 months allows for the rejection of the null hypothesis in this trial that the true EFS was 32 months.
  - However, a longer follow-up period is needed to confirm the observed survival improvement.
- The outcomes are similar to other prospective international trials of pediatric regimens in AYA patients (Proc ASH 2013;Abstract 839; JCO 2009;27:911; JCO 2008;26:1843).

Stock W et al. Proc ASH 2014;Abstract 796.

Author Conclusions (Continued)

- The presence of the BCR-ABL1-like signature and CRLF2 overexpression (data not shown) are common and associated with significantly worse survival outcomes.
- The absence of MRD after induction therapy was associated with excellent DFS.
- Future directions include the use of a C10403 pediatric regimen as the foundation for future studies for AYA patients with ALL in US Intergroup trials, representing a shift in approach to treating AYA ALL.
- The goal of future studies is to incorporate new targeted antibodies/kinase inhibitors into treatment, eradicate MRD and improve survival in AYA ALL.

Stock W et al. Proc ASH 2014;Abstract 796.
Investigator Commentary: Results of the Phase II C10403 Trial for Older AYA Patients with ALL

This is one of the more exciting studies to come out of ALL in a while. This was a huge effort across the US Intergroups to answer a fundamental question that’s been circulating for a few years. Retrospective studies have reported that adolescents and young adults, defined variably as patients from age 16 to 39 years, seem to perform better when treated with pediatric protocols compared to adult protocols. Was this due to the fact that different agents were being used in the pediatric protocols or that adult patient oncologists were not as rigorous in keeping patients on therapies or were not dose reducing?

Patients (ages 16-39) received treatment using a Children’s Oncology Group regimen, but treatment was administered by adult oncologists through the adult cooperative groups. We do not yet have a head-to-head comparison of similarly aged patients treated by pediatricians as opposed to adult oncologists, but the study reported that toxicities were similar to those reported in the standard arm of the pediatric COG AALL0232 protocol, with an increase in thrombosis and hyperbilirubinemia.

*Interview with Mikkael A Sekeres, MD, MS, January 20, 2015*

continued

Investigator Commentary: Results of the Phase II C10403 Trial for Older AYA Patients with ALL

The median EFS was 59 months and the 2-year EFS was 66%. The 2-year OS rate was 79% and the median OS has not yet been reached. Notably, the 2-year EFS and OS rates were high. The predictors for worse outcome were age greater than 20, initial white blood cell counts greater than 30,000, the presence of MRD at day 28 after induction therapy and Ph+-like gene expression. The assessment of MRD after induction therapy in order to make treatment decisions is increasingly becoming the standard for ALL therapy. In the Cleveland Clinic, our standard in this age group of patients has now become to administer treatment on this protocol. Anyone who walks into the Cleveland Clinic to our adult group aged 17 to 39 years is receiving this regimen. We’re impressed by the outcomes so far, with limited follow-up, and now it is also our standard practice to assess MRD in patients.

*Interview with Mikkael A Sekeres, MD, MS, January 20, 2015*